A blood clotting time measurement cartridge includes: an inlet on one end of a measurement flow channel and through which blood is introduced; a communication opening on the other end of the measurement flow channel and through which air suction or air pressure application or the blood introduced from the inlet is performed; a moving body arranged in the measurement flow channel moves; a clotting accelerator applied on at least one of a flow channel wall surface, which defines the measurement flow channel, and the moving body; and a detection area through which light is transmitted to a predetermined part in the measurement flow channel, and where it is possible to detect with light whether there is the moving body or the blood making a reciprocating motion in the measurement flow channel in association with air suction or air pressure application or the blood from the communication opening.

A blood clotting time measurement cartridge includes: an inlet on one end of a measurement flow channel and through which blood is introduced; a communication opening on the other end of the measurement flow channel and through which air suction or air pressure application or the blood introduced from the inlet is performed; a moving body arranged in the measurement flow channel moves; a clotting accelerator applied on at least one of a flow channel wall surface, which defines the measurement flow channel, and the moving body; and a detection area through which light is transmitted to a predetermined part in the measurement flow channel, and where it is possible to detect with light whether there is the moving body or the blood making a reciprocating motion in the measurement flow channel in association with air suction or air pressure application or the blood from the communication opening.

The present invention relates to a method of diagnosing a human sepsis. The present invention further relates to a kit for diagnosing a human sepsis. The present invention also relates to a point-of-care device for performing a method of diagnosing a human sepsis. The present invention also relates to a use of a kit and/or a point-of-care device for a method of diagnosing a human sepsis. The present invention also relates to the use of a kit and/or a point-of-care device for a method of diagnosing a human sepsis. The method comprises stimulating a platelet-specific (hem-)ITAM receptor by adding a (hem-)ITAM receptor agonistic agent to a blood sample of a patient, wherein said agonistic agent comprises CRP-XL and/or convulxin, and measuring a platelet function level.

Novel methods for preventing, reducing the risk of development of, and for treating hypercoagulopathy in Cushing's syndrome patients with elevated risk of developing hypercoagulopathy are disclosed. The methods are further useful to prevent, to reduce the risk of developing, and to treat deep vein thrombosis (DVT), pulmonary embolism (PE), and venous thromboembolism (VTE); and to treat inflammatory states. The methods include: administering heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (HKGRM) to a Cushing's syndrome patient at risk of developing hypercoagulopathy, thereby treating hypercoagulopathy. Methods of preventing, reducing risk of developing, and of treating DVT, PR, or VTE in a Cushing's syndrome patient comprise administering a HKGRM to the patient. Methods of unmasking and subsequently reducing an inflammatory state comprise administering an effective amount of a HKGRM to a Cushing's syndrome patient, effective first to increase inflammatory symptoms and then to subsequently decrease said inflammatory symptoms in the patient.

A method for diagnosing a malignant proliferative disease or disorder in a subject, and/or for following up, monitoring or prognosticating the therapy of a malignant proliferative disease or disorder in a subject is disclosed. The method is based on measurement of platelet-mediated fibrinogen-like protein 2 (FGL2) activity in a sample essentially comprising platelets obtained from the subject. In accordance with the disclosed method, platelet-mediated FGL2 activity level higher than control is indicative of the presence of a malignant proliferative disease or disorder in a subject.

A method for diagnosing a malignant proliferative disease or disorder in a subject, and/or for following up, monitoring or prognosticating the therapy of a malignant proliferative disease or disorder in a subject is disclosed. The method is based on measurement of platelet-mediated fibrinogen-like protein 2 (FGL2) activity in a sample essentially comprising platelets obtained from the subject. In accordance with the disclosed method, platelet-mediated FGL2 activity level higher than control is indicative of the presence of a malignant proliferative disease or disorder in a subject.

Provided herein are compositions and methods for quantifying polyphosphates. In particular, provided herein are solution and substrate based assays for quantifying polyphosphates in complex samples.

Provided herein are compositions and methods for quantifying polyphosphates. In particular, provided herein are solution and substrate based assays for quantifying polyphosphates in complex samples.

Devices and methods for determining activity of one or more coagulation factors in a blood sample are provided. The device may comprise an inlet port for deposition of a sample, a reaction compartment, a detection compartment, a control compartment, or any combination thereof. One or more compartments may be fluidically connected. One or more compartments may comprise plasma deficient of a coagulation factor, an ionic citrate source, an ionic calcium source, one or more coagulation contact phase activator reagents, a phospholipid, or a mixture, or any combination thereof.

Devices and methods for determining activity of one or more coagulation factors in a blood sample are provided. The device may comprise an inlet port for deposition of a sample, a reaction compartment, a detection compartment, a control compartment, or any combination thereof. One or more compartments may be fluidically connected. One or more compartments may comprise plasma deficient of a coagulation factor, an ionic citrate source, an ionic calcium source, one or more coagulation contact phase activator reagents, a phospholipid, or a mixture, or any combination thereof.